Drug Profile
Research programme: deuterium-containing therapeutics - Concert Pharmaceuticals
Alternative Names: C-10068; C-20081; C-21246; C-21359; CTP-221; D-apremilast; D-boceprevir; D-cilostazol; D-darunavir; D-iloprost; D-lenalidomide; D-linezolid; D-ranolazineLatest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Concert Pharmaceuticals
- Developer Concert Pharmaceuticals; GSK
- Class Neuroprotectants; Organic deuterium compounds; Oxazolidinones; Small molecules; Sodium compounds; Sulfonamides; Synthetic prostaglandins
- Mechanism of Action Angiogenesis inhibitors; Epoprostenol agonists; GABA A receptor modulators; Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors; HIV protease inhibitors; Immunomodulators; Interleukin 1 beta stimulants; Interleukin 10 stimulants; Partial fatty acid oxidation inhibitors; Platelet aggregation inhibitors; Protein 30S ribosomal subunit inhibitors; Pyruvate dehydrogenase stimulants; Sigma-1 receptor agonists; Tumour necrosis factor inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Epilepsy; Hepatitis C; HIV infections; Inflammation; Kidney disorders; Methicillin-resistant Staphylococcus aureus infections; Neuropathic pain; Pulmonary arterial hypertension
Most Recent Events
- 06 Mar 2023 Concert Pharmaceuticals has been acquired by Sun Pharmaceutical Industries
- 11 Mar 2022 Terran Biosciences acquires Concert Pharmaceuticals' CNS therapeutics portfolio and intellectual property rights
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA